Welcome to Madrid and join us to discuss one of the most rapidly evolving field in lymphoma, with a great speakers line-up. Hope@to meet you there!

A very comprehensive review on R/R MCL treatment approach after BTKi failure by Eva Gine from Hematología Hospital Clínic Barcelona presented at #EHA2024 #MCL

Waldenström lymphoma: Therapy of relapsed/refractory disease by Christian Buske #EHA2024

STARGO trial: Glofitamab + GemOx vs. R-GemOx in R/R DLBCL transplant ineligible #EHA2024 - N=274 - 56% primary refractory - Higher CR rate in Glofi-GemOx arm (50.3% vs. 22.0%; p<0.0001) - OS benefit (median OS NE vs. 9 mo) What is the role of this combination in CAR T era?

Wang - Echo study #EHA2024 - BR v Acala-BR in 1L Mantle, 65y+ - randomised, double blind, plac-contr - Clear PFS benefit: 27% reduction PD / death - Trend to OS but not stat sig even when COVID deaths removed - low cardiac events, slightly more inftn New SOC? #lymsm

CONGRESS #EHA2024 | Peter Borchmann #cioabcd presents the final analysis of phase III #HD21 trial of PET2-individualized BrECADD regimen vs intensified BEACOPP in patients with advanced-stage #HodgkinLymphoma. BrECADD had superior efficacy (PFS 94.3% vs 90.9% at 4 yr) with

Feeling incredibly lucky to have these two amazing mentors and to enjoy such a wonderful evening together #EHA2024

📢Registration to the 18-ICML is open! Don't miss the opportunity to participate in the only international conference that focuses exclusively on #lymphoidneoplasms! 🔗Register now: shorturl.at/LHtyT

I’m thrilled that our work reporting the efficacy and unique mechanism of action of romidepsin and duvelisib in T cell lymphoma is out today in Nature Medicine (rdcu.be/dK2g8). A short thread:

Best team 🤩👏🏻👏🏻🤩!!!

The U.S. FDA granted accelerated approval to the immunotherapy epcoritamab-bysp for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy: bit.ly/3L2gWTx

🎓 Elías Campo investit doctor honoris causa per la Universitat UT3 Paul Sabatier. 🗣️ “És un honor rebre aquest reconeixement d’una institució tant prestigiosa que consolida la relació científica i col·laboracions que mantenim des de fa mes de 25 anys” 👉 i.mtr.cool/efmstvdkww

B-cells from CR patients expressed higher levels of MS4A1 (unsprisingly) but also had very high levels of IFN response programs, including STAT1, IRF1, and MHC-II.

#NuevaFotoDePerfil

A historic day for Spanish sport! 🇪🇸🏆🎾⚽: - Carlos Alcaraz wins Wimbledon - Spain's soccer team triumphs in the 2024 European Championship! #España #Wimbledon #EURO2024

SPOTLIGHT REVIEW Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma Megan Melody Leo I. Gordon Haematologica haematologica.org/article/view/h…

Summer BBQ in NYC Scherz Shouval Lab next generation. What a great afternoon Memorial Sloan Kettering Cancer Center

Treatment of newly diagnosed myeloma in one slide. Based on 4 recent phase IIIs practice has changed and has become easier. #MyelomaVR

Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma - Annals of Oncology annalsofoncology.org/article/S0923-…

Qué profunda tristeza. Me duele mi país. Y para quienes están celebrando, o guardando silencio complice, o refiriéndose a la captura del poder judicial como un “experimento”, solo señalo las características del régimen que han creado: Sin contrapesos institucionales. Sin